Drug Database
SH

SH-U-454

✓ Approved

Bayer AG · Small Molecule · Small Molecule

What is SH-U-454?

SH-U-454 is a small molecule developed by Bayer AG. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyBayer AG
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

SH-U-454 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersArteriosclerosis coronary artery✓ Approved

Related Research Articles

PubMedACS applied materials & interfaces2026-11-11

Phosphate-Functionalized Macroporous Cellulose Sponges for Uranium Recovery from Seawater.

Sekine Yurina Y, Nankawa Takuya T, Sugita Asako A, Konda Miki M et al.

Cellulose-based adsorbents offer a sustainable platform for uranium recovery from seawater, but simple functionalization strategies that enable effective uranium capture under highly competitive marine conditions remain limited. Here, we report a post-phosphorylation strategy for introducing uranium-binding functionality into a preformed freeze-crosslinked carboxymethyl cellulose nanofiber (CMCF) sponge while retaining its interconnected macroporous architecture. Impregnation of the cellulose sponge with NH4H2PO4/urea followed by mild thermal treatment at 120 °C introduced up to 114 ± 18 mg P g-1 sponge. In seawater spiked with 10 mg L-1 U(VI), both nonphosphorylated and phosphorylated CMCF sponges showed similarly high U removal (>96%), largely obscuring the effect of phosphate functionalization. In contrast, a pronounced phosphate-dependent enhancement emerged under realistic seawater conditions: the nonphosphorylated sponge showed negligible U removal from natural seawater, whereas the post-phosphorylated P1-CMCF sponge achieved approximately 99% U removal within 24 h. SEM-EDX and XPS analyses further supported uranium accumulation at phosphate-rich cellulose interfaces and the involvement of phosphate-associated oxygen donor sites in U binding. The captured uranium was nearly quantitatively recovered using 0.1 mol L-1 NaHCO3, and adsorption performance was maintained over three adsorption-desorption cycles. These results demonstrate that simple post-phosphorylation of a preformed macroporous cellulose scaffold provides accessible uranium-binding interfaces while preserving the underlying transport architecture, offering a straightforward route to efficient and regenerable uranium recovery under chemically complex seawater conditions.

PubMedFrontiers in medicine2026-11-11

Herpes zoster-induced critical rhabdomyolysis with secondary hypothyroidism: a case report.

Lv Xiangkang X, Zhang Bin B, Yang Wei W, Lu Xiao X

Primary varicella-zoster virus (VZV) reactivation causes herpes zoster (HZ), typically presenting with dermatomal rash and neuropathic pain. Rhabdomyolysis as a systemic complication of HZ is extremely rare, and its underlying pathogenesis and optimal management remain poorly characterized, especially in elderly patients. Here we report a 63-year-old female who presented with fever, generalized myalgia, and oliguria, with serum creatine kinase (CK) rapidly escalating from 4,383 U/L to a peak of 186,383 U/L. Further investigation revealed a preceding history of lumbar herpes zoster two weeks prior, accompanied by virus-induced secondary hypothyroidism. Muscle biopsy confirmed extensive myofiber necrosis without inflammatory infiltration, consistent with non-inflammatory rhabdomyolysis. The patient developed acute kidney injury, hepatic dysfunction, and respiratory failure, and was managed with multidisciplinary intensive care including mechanical ventilation, 9 days of continuous renal replacement therapy, glucocorticoid anti-inflammatory therapy, and levothyroxine replacement. After 12 days of treatment, CK decreased to 3,381 U/L with significant recovery of multiorgan function, and the patient was transferred out of the intensive care unit. This case highlights that HZ can trigger life-threatening rhabdomyolysis, possibly via VZV-mediated immune dysregulation and secondary hypothyroidism. Detailed history taking, early CK screening, and multidisciplinary organ support are critical to improve outcomes in this rare but severe condition.

PubMedFrontiers in oncology2026-11-11

Case Report: Cholestatic liver injury during atezolizumab therapy in EGFR-mutant combined small cell lung cancer with possible underlying primary biliary cholangitis.

Zhu Yingqiong Y, Xiong Jin J, Tan Chuan C, Tan Benxu B et al.

Combined small cell lung cancer (C-SCLC) may coexist with EGFR driver mutations. For extensive-stage disease, PD-L1 inhibitor plus platinum-etoposide is first-line. Immune checkpoint inhibitor (ICI)-associated cholangiopathy is a rare immune-related adverse event hard to distinguish from pre-existing autoimmune biliary disease such as primary biliary cholangitis (PBC) when baseline serology and histology are unavailable. A 68-year-old male former smoker presented with an incidentally detected right upper lobe mass. CT-guided percutaneous biopsy showed C-SCLC with a small adenocarcinoma component, neuroendocrine marker positivity, and loss of Rb, and next-generation sequencing revealed an EGFR exon 21 L858R mutation (mutant allele frequency 60.78%). The disease was classified as extensive-stage C-SCLC. First-line etoposide, carboplatin, and atezolizumab (four cycles) achieved partial response; alkaline phosphatase rose from mildly elevated baseline (156 U/L) to 532 U/L and gamma-glutamyl transferase from 87 to 317 U/L, with mild transaminase elevation and normal total bilirubin, a cholestatic pattern (CTCAE v5.0 grade 2). AMA-M2 was positive, raising the possibility of a previously unrecognized PBC background. Imaging showed no biliary dilatation, steatosis, or advanced fibrosis, but magnetic resonance cholangiopancreatography, liver biopsy, and pre-treatment autoantibody testing were not performed. Atezolizumab was stopped and ursodeoxycholic acid continued without high-dose corticosteroids. The cholestatic enzymes fell thereafter, but neither an underlying PBC nor a contribution from superimposed ICI-related biliary injury could be established. Consolidative thoracic radiotherapy and concurrent maintenance with furmonertinib and oral etoposide followed. At the last follow-up on July 28, 2026, partial response was maintained. This patient with EGFR-mutant C-SCLC was managed with SCLC-directed chemo-immunotherapy then maintenance with EGFR tyrosine kinase inhibitor after cholestatic liver injury. AMA-M2 positivity with pre-existing cholestatic abnormalities raises the possibility of an underlying PBC, but without pre-treatment serology, magnetic resonance cholangiopancreatography, or liver biopsy, neither a definite PBC background nor a definite ICI-related cholangiopathy could be established. Cholestatic liver injury during immunotherapy warrants evaluation for autoimmune biliary disease and drug-related biliary injury.

PubMedAnalytical chemistry2026-11-11

Nanopipette Sensing of APE1 Activity via Enzymatic Recycling and DNA Tetrahedron-Streptavidin Reporting: Profiling in Cancer Diagnostics, Oxidative Stress, and Cell Cycle.

Liu Junli J, Duan Zhijuan Z, Gong Xianyan X, Xia Fan F et al.

Apurinic/apyrimidinic endonuclease 1 (APE1) is a clinical biomarker whose small molecular size hinders direct detection by conventional nanopores (30 nm). Here, we report a nanopipette platform integrating APE1-driven enzymatic recycling amplification with DNA tetrahedron-streptavidin (TDN-SA) complex-based resistive-pulse reporting to overcome this size limitation. APE1 specifically cleaves hairpin DNA probes, generating output strands that displace biotin-modified DNA oligo from the TDN-SA complex, reducing translocation event frequency in 30 nm nanopipettes. This signal modulation enables APE1 quantification with a detection limit of 10-5 U/mL and a linear range spanning 7 orders of magnitude (10-5 to 10 U/mL). The method discriminates APE1 activity between normal and cancer cell lines (HeLa, MCF-7, A549 vs. 293T, MCF-10A), tracks oxidative stress-induced elevation (0-4 h H2O2 treatment), and reveals cell cycle-dependent regulation (lowest in G0/G1, peaking in S phase). Furthermore, the system evaluates APE1 inhibition by 7-nitroindole-2-carboxylic acid in inflammatory macrophages, demonstrating its utility for drug efficacy assessment. This label-free platform overcomes the protein size constraint of traditional nanopore methods, offering a versatile tool for profiling low-abundance protein biomarkers in native cellular contexts.

PubMedMedicine2026-11-11

Anti-SRP and anti-HMGCR co-positivity in immune-mediated necrotizing myopathy with interstitial lung disease: A rare case report.

Imran Muhammad M, Javaid Muhammad Hassaan MH, Fareh Zohad Z, Wazir Maryam Alam MA et al.

Immune-mediated necrotizing myopathy (IMNM) is a rare inflammatory myopathy. Coexisting anti-signal recognition particle (anti-SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies in statin-naïve patients with interstitial lung disease are exceptionally uncommon. A 55-year-old statin-naïve man presented with progressive proximal muscle weakness, dysphagia, myalgia, significant weight loss, and exertional dyspnea. Serum creatine kinase was 8000 U/L. Anti-SRP, anti-HMGCR, and anti-Ro52 antibodies were positive. Chest computed tomography showed bilateral consolidations and ground-glass opacities suggestive of organizing pneumonia. Pulmonary function tests revealed reduced forced vital capacity (52%) and diffusing capacity for carbon monoxide (48%). Electromyography and muscle biopsy findings supported IMNM. Treatment included high-dose corticosteroids, mycophenolate mofetil, nutritional support, and rehabilitation. After 3 months, muscle strength improved from 3/5 to 4+/5, dysphagia resolved, and weight increased by 5 kg. Creatine kinase decreased to 350 U/L, forced vital capacity improved to 74%, and diffusing capacity for carbon monoxide to 65%. Follow-up high-resolution computed tomography showed pulmonary improvement without fibrosis. This case highlights the rare coexistence of anti-SRP and anti-HMGCR antibodies in statin-naïve IMNM with interstitial lung disease. Early immunosuppression, nutritional support, and rehabilitation may improve muscular and pulmonary outcomes. Comprehensive respiratory assessment and longitudinal monitoring are essential.

PubMedBMC oral health2026-11-11

Analysis of salivary amylase level in tobacco smokers with tobacco-associated mucosal lesions of the oral cavity: a case-control study.

Shetty Prathima P, Shirin Mariyam M, K M Veena V, Chatra Laxmikanth L et al.

Saliva is the first biological fluid to come into contact with tobacco smoke in smokers. Upon contact with saliva, tobacco smoke increases the production of reactive nitrogen species, thereby altering enzymatic activity. As a result, the protective functions of saliva are impaired, contributing to the development of oral pathologies. Evidence suggests that there is alteration in salivary amylase level in smokers, however the views are divergent. Hence, this study was carried out with the aim to analyze salivary amylase level in tobacco smokers with tobacco associated mucosal lesions of the oral cavity. A total of 80 patients were selected and divided into two groups of 40 smokers with tobacco associated mucosal lesions of the oral cavity (Cases) and 40 smokers without tobacco associated mucosal lesions of the oral cavity (Controls). Unstimulated saliva was collected from these patients and amylase level was estimated using CNPG3 method. The mean salivary amylase activity was 981.77 U/mL in the case group and 1116.28 U/mL in the control group. Independent t test was used to compare amylase levels between the groups. A statistically significant difference in mean salivary amylase levels between the groups with p < 0.001 was observed. A statistically significant reduction in salivary amylase levels was observed in tobacco smokers with tobacco-associated oral mucosal lesions compared with tobacco smokers without lesions. Reduction in amylase level may indicate that smoking can predispose oral mucosa to tobacco associated lesions.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SH-U-454